These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Determination of Protein-Protein Interactions in a Mixture of Two Monoclonal Antibodies. Singh P; Roche A; van der Walle CF; Uddin S; Du J; Warwicker J; Pluen A; Curtis R Mol Pharm; 2019 Dec; 16(12):4775-4786. PubMed ID: 31613625 [TBL] [Abstract][Full Text] [Related]
10. X-ray Scattering and Coarse-Grained Simulations for Clustering and Interactions of Monoclonal Antibodies at High Concentrations. Dear BJ; Bollinger JA; Chowdhury A; Hung JJ; Wilks LR; Karouta CA; Ramachandran K; Shay TY; Nieto MP; Sharma A; Cheung JK; Nykypanchuk D; Godfrin PD; Johnston KP; Truskett TM J Phys Chem B; 2019 Jun; 123(25):5274-5290. PubMed ID: 31146525 [TBL] [Abstract][Full Text] [Related]
12. How Well Do Low- and High-Concentration Protein Interactions Predict Solution Viscosities of Monoclonal Antibodies? Woldeyes MA; Qi W; Razinkov VI; Furst EM; Roberts CJ J Pharm Sci; 2019 Jan; 108(1):142-154. PubMed ID: 30017887 [TBL] [Abstract][Full Text] [Related]
13. Solubility Challenges in High Concentration Monoclonal Antibody Formulations: Relationship with Amino Acid Sequence and Intermolecular Interactions. Pindrus M; Shire SJ; Kelley RF; Demeule B; Wong R; Xu Y; Yadav S Mol Pharm; 2015 Nov; 12(11):3896-907. PubMed ID: 26407030 [TBL] [Abstract][Full Text] [Related]
14. Coarse-Grained Antibody Models for "Weak" Protein-Protein Interactions from Low to High Concentrations. Calero-Rubio C; Saluja A; Roberts CJ J Phys Chem B; 2016 Jul; 120(27):6592-605. PubMed ID: 27314827 [TBL] [Abstract][Full Text] [Related]
15. Predicting Protein-Protein Interactions of Concentrated Antibody Solutions Using Dilute Solution Data and Coarse-Grained Molecular Models. Calero-Rubio C; Ghosh R; Saluja A; Roberts CJ J Pharm Sci; 2018 May; 107(5):1269-1281. PubMed ID: 29274822 [TBL] [Abstract][Full Text] [Related]
16. From osmotic second virial coefficient (B22 ) to phase behavior of a monoclonal antibody. Rakel N; Bauer KC; Galm L; Hubbuch J Biotechnol Prog; 2015; 31(2):438-51. PubMed ID: 25683855 [TBL] [Abstract][Full Text] [Related]
17. Identifying Key Residues That Drive Strong Electrostatic Attractions between Therapeutic Antibodies. Ferreira GM; Shahfar H; Sathish HA; Remmele RL; Roberts CJ J Phys Chem B; 2019 Dec; 123(50):10642-10653. PubMed ID: 31739660 [TBL] [Abstract][Full Text] [Related]
18. Toward a Suite of Coarse-Grained Models for Molecular Simulation of Monoclonal Antibodies and Therapeutic Proteins. Shahfar H; Forder JK; Roberts CJ J Phys Chem B; 2021 Apr; 125(14):3574-3588. PubMed ID: 33821645 [TBL] [Abstract][Full Text] [Related]
19. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering. Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466 [TBL] [Abstract][Full Text] [Related]
20. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools. Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]